• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • Experts on Demand
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

World Alzheimer’s Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends), The

$1,500.00 – $4,995.00

Clear
SKU: KLI1614113 Categories: Drug Discovery Market Reports, Pharmaceuticals Market Research Pages: 125
  • Description
  • Table of Contents
  • Latest reports

Description

Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer’s Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study.

This report includes incidence of Alzheimer’s disease worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market.

Information is presented as a worldwide overview, with special emphasis on the U.S., Japan, Germany, and other key markets.

A market summary includes market analysis by products on the market and in development, in addition to a a regional market analysis, including:

  • US
  • Europe
  • Japan
  • Rest of World

 

as well as a competitive analysis of leading providers. Additionally key company profiles are included, with profiles of the following companies competing in this therapeutic area:

 

  • Eisai Co., Ltd.
  • Forest Laboratories
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merz Pharma GmbH
  • Novartis AG
  • Pfizer, Inc.

 

Markets are broken out by drug type:

 

  • Cholinesterase inhibitors
  • NMDA antagonists

 

as well as by product.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2007. Historical data was provided for the years 2005 and 2006, with forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs) are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment covered. Competitive analysis is provided for the year 2007.

Table of Contents

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Background
  • Scope and Methodology
  • Size and Growth of the Market
  • Key Issues and Trends Affecting Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION

  • Overview
  • Structural Organization of the Neurological System
    • Central Nervous System
    • The Brain
  • Aging and Alzheimer’s Disease
  • Stages of Alzheimer’s Disease
  • Risk Factors
  • Life Expectancy and the Growing Incidence of Alzheimer’s Disease
  • World Demographics
  • Prevalence, Incidence and Mortality
  • Insurance for the Elderly in the United States
  • Generic Competition
    • Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai
    • Dr. Reddy’s and Novartis
    • Ranbaxy and Ortho-McNeil Neurologics

CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS

  • Overview of Products
  • Aricept
  • Namenda/Exiba/Axura
  • Exelon
  • Razadyne
  • Other Products

CHAPTER FOUR: RESEARCH AND DEVELOPMENT

  • Overview
  • Phase III
    • AAB-001
    • Aricept SR
    • Exelon Transdermal Patch (ONO 2540)
    • Flurizan
    • LY450139
    • Memryte
    • Namenda Once-Daily
    • Rosiglitazone XR
    • Xaliproden
  • Phase II
    • Dimebon
    • AC-1202
    • Ispronicline
    • MEM-3454
    • MEM-1003
    • AN-1792
    • ABT-089
    • ACC-001 and QS-21
    • AL-108
    • CX717
    • ELND-005
    • Huperzine A
    • Immune globulin, intravenous
    • LY2062430
    • Lecozotan SR
    • MK-0249
    • MK-0952
    • Neramenxane
    • NIC5-15
    • PRX-03140
    • Rasagiline mesylate
    • SAM-531
    • SGS742
    • T 817 MA
    • TTP 488
  • Phase I
    • 933776
    • Aricept Transdermal Patch
    • AV 965
    • AVE 8112
    • Bapineuzumab
    • CAD-106
    • CERE-110
    • CTS-21166
    • EVP 6124
    • GSI 953
    • Lecozotan SR
    • MEM-1414
    • NGX267
    • Oxigon
    • Paz-417
    • PF-4360365
    • PF-30804014
    • R1450
    • R4996/MEM 63908
    • SSR 180711
    • V 950
  • Preclinical Development
    • TTP 4000
    • AAB-002
    • Alzhemed
    • BACE Inhibitors (TTP 854)
    • CX1739
    • E2012
    • Gamma-secretase inhibitor
    • GSI-136
    • MEM-1917
    • MPI-442690
    • PBT2/PBT3/PBT4
    • SAR 110894

CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS

  • Market Overview
  • Market Analysis by Product Type
  • Market Analysis by Country
  • Competitive Analysis
  • Leading Products

CHAPTER SIX: LEADING MANUFACTURERS

  • Overview
  • Eisai Co., Ltd.
  • Forest Laboratories
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merz Pharma GmbH
  • Novartis AG
  • Pfizer, Inc.

APPENDIX: LIST OF MAJOR COMPANIES LIST OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY

  • Figure 1-1: Alzheimer’s Disease Market Analysis: 2005-2012

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Alzheimer’s Disease Stages 1-7 and Descriptions
  • Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2006
  • Figure 2-1: Average Life Expectancy in Years by Country 1980, 2004 and 2006
  • Table 2-3: World Population by Selected Geographical Region, 2007 – 2050
  • Figure 2-2: World Population by Selected Geographical Region, 2007-2050
  • Table 2-4: Estimated World Population by Age and Geographical Region, 2007
  • Figure 2-3: Estimated World Population by Age and Geographical Region, 2007
  • Table 2-5: Percent Population Over 65 by Year and Region
  • Figure 2-4: Estimated World Population by Age, 2007 and 2050
  • Table 2-6: Estimated Prevalence, Incidence and Mortality for Alzheimer’s Disease* by Region/Country, 2007
  • Figure 2-5: Estimated World Prevalence and Incidence of Alzheimer’s Diseases by Region, 2007
  • Figure 2-6: World Prevalence of Alzheimer’s Disease Compared to Rest of Population Over Age 65, 2007
  • Table 2-7: Health Insurance Trends in the United States, Estimated 2007 (millions)

CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS

  • Table 3-1: Comparison of Marketed Alzheimer’s Disease Treatments
  • Figure 3-1: Alzheimer Product Sales Analysis, 2005-2007
  • Figure 3-2: Aricept Sales Analysis, 2005-2007
  • Figure 3-3: Namenda/Exiba/Axura Sales Analysis, 2005-2007
  • Figure 3-4: Exelon Sales Analysis, 2005-2007
  • Figure 3-5: Razadyne Sales Analysis, 2005-2007

CHAPTER FOUR: RESEARCH AND DEVELOPMENT

  • Figure 4-1: Alzheimer’s Disease Treatments in Development, 2005, 2006, and 2007
  • Table 4-1: Alzheimer’s Disease Therapies in Development

CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS

  • Table 5-1: Alzheimer’s Disease Market Analysis, 2005-2007
  • Table 5-2: Forecasted Alzheimer’s Disease Market Analysis: 2008-2012
  • Figure 5-1: Alzheimer’s Disease Market Analysis: 2005-2012
  • Table 5-3: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
  • Figure 5-2: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
  • Figure 5-3: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005 Figure 5-4: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2007
  • Table 5-4: Alzheimer’s Disease Market Analysis by Region/Country, 2007
  • Figure 5-5: Alzheimer’s Disease Market Analysis by Region/Country, 2007
  • Table 5-5: Alzheimer’s Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007
  • Figure 5-6: Alzheimer’s Disease Market Estimated Market Share by Leading Suppliers 2007
  • Table 5-6: Alzheimer’s Disease Market Estimated Sales of Top Products 2007
  • Figure 5-7 : Alzheimer’s Disease Market Estimated Market Share of Top Products, 2007

CHAPTER SIX: LEADING MANUFACTURERS

  • Figure 6-1: Eisai’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-2: Forest’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-3: Lundbeck’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-4: Johnson & Johnson’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-5: Merz Pharma’s Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-6: Novartis’ Net Revenues and R&D Expenses for 2006 and 2007
  • Figure 6-7: Pfizer’s Net Revenues and R&D Expenses for 2006 and 2007

 

    In Vitro Toxicology Market
    July 19, 2018
    100 Companies in Contract Pharmaceutical Research – White Paper
    March 27, 2018
    Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 8th Edition
    March 20, 2018
    Outsourcing in Drug Discovery, 7th Edition
    April 26, 2016

Related products

  • Placeholder image

    OTC Women’s Health: A Supplement to Women’s Health, 3rd Edition

    $1,496.00 – $2,992.00
  • Placeholder image

    U.S. Market for OTC Diet Aids, The

    $3,000.00 – $6,000.00
  • Placeholder image

    Market for Generic Biologics: Issues, Trends, and Market Potential, The

    $1,500.00 – $3,000.00
  • Placeholder image

    World Market for Anti-infectives Series: Volumes I – III – Antifungals, Antibacterials and Antivirals, The

    $6,000.00 – $12,000.00

Contact Us

  •  Email Us: Customer Service

  •  Phone (US):  703-778-3080

  •  Fax:  703-778-3081

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • Global Medtech Sales Exceed $500 Billion as Chronic Diseases Shape Market’s Future November 14, 2023
  • Healthcare Advances, Investments Support Laboratory Information System (LIS) Growth October 26, 2023
  • Personalized Medicine Key to IVD Procedure Volumes’ 10% Annual Growth October 19, 2023
  • RNA Sequencing: Life Sciences’ Transformative $2.6 Billion Industry October 4, 2023
  • How Globalization and Climate Change Impact COVID-19 and the IVD Market September 20, 2023

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Facial Rejuvenation Markets WorldwideMinimally Invasive Surgical Devices, World Market
Scroll to top